HealthEquity (HQY) fundamentals: P/E, valuation, undervalued?
HealthEquity · Health Care · ref. ETF XLV · price $90.19
In short — HealthEquity trades at 32.6× earnings (P/E), 16.4× forward, with a net margin of 17.4 % and revenue growth of +8 %. Read: Fairly valued (P/E 16 in line with ~15% growth (PEG 1.1)).
Is HealthEquity stock cheap or undervalued? A good time to buy? Here are its fundamentals — P/E, PEG, margin and income statement — to judge its valuation.
📈 1-year price
$90.19-4.1% over range
Oct 14, 25low $73.21 · high $106.79Oct 13, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Buy
100% recommend buying · 6 analysts
Valuation : Fairly valued — P/E 16 in line with ~15% growth (PEG 1.1)
Valuation
32.6
P/E (price/earnings)
16.4
Forward P/E
2.21
PEG
3.8
Price/book (P/B)
$7.5B
Market cap
2.77
EPS
Profitability & growth
17.4 %
Net margin
+8 %
Revenue growth
+15 %
Earnings growth
$971M
Total debt
HealthEquity income statement
| Fiscal year | Revenue | Net income | Margin |
|---|---|---|---|
| 2023 | $862M | $-26M | -3.0 % |
| 2024 | $1000M | $56M | 5.6 % |
| 2025 | $1.2B | $97M | 8.1 % |
| 2026 | $1.3B | $215M | 16.4 % |
⚠️ Indicative financial data (Yahoo Finance), not investment advice. Amounts in $.
Frequently asked questions
What is HealthEquity's P/E and is the stock undervalued? What's a good P/E?
HealthEquity's P/E is 32.6 (forward 16.4). Below ~15 = fairly cheap, above ~30 = expensive. Our valuation verdict: "Fairly valued".
Is HealthEquity profitable?
HealthEquity has a net margin of 17.4 % (EPS 2.77). The company is profitable.
Is HQY stock expensive?
Our read: "Fairly valued" — P/E 16 in line with ~15% growth (PEG 1.1). Cross-check with growth and sector.
💬 A question about HealthEquity? The JPI assistant answers using our backtest data.
Keep exploring HealthEquity